Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.

布仑妥昔单抗维多汀 ABVD公司 达卡巴嗪 医学 长春碱 内科学 化疗方案 阶段(地层学) 肿瘤科 化疗 外科 淋巴瘤 胃肠病学 霍奇金淋巴瘤 长春新碱 环磷酰胺 古生物学 生物
作者
Howland E. Crosswell,Ann S. LaCasce,Nancy L. Bartlett,David J. Straus,Kerry J. Savage,Pier Luigi Zinzani,Graham P. Collins,Michelle A. Fanale,Keenan Fenton,Cassie Dong,Harry Miao,Andrew Grigg
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): 7528-7528 被引量:1
标识
DOI:10.1200/jco.2021.39.15_suppl.7528
摘要

7528 Background: Hodgkin lymphoma (HL) is a rare disease that commonly occurs in adolescents and young adults (AYAs) which is typically defined as 15 to 39 years. Given their young age at presentation, key factors in treatment selection include a high cure rate and limiting long-term toxicities. Brentuximab vedotin (Adcetris®; A) is a CD30-directed ADC approved in combination with doxorubicin, vinblastine, and dacarbazine chemotherapy (A+AVD) for adults with previously untreated stage III/IV cHL based on results from the phase 3 ECHELON-1 trial. Recent 5-year data demonstrated a significantly improved PFS per investigator (INV) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) (HR, 0.69; 95% CI, 0.54–0.9; P = 0.003) (Straus 2020). Here we describe key efficacy and safety results for AYA pts enrolled in ECHELON-1. Methods: ECHELON-1 (N = 1334) is a global, open-label, multicenter, randomized trial of pts with previously untreated stage III/IV cHL. A total of 771 AYAs (57.8%) received either A+AVD (n = 396) or ABVD (n = 375) with a PET scan after cycle 2 (PET2). An analysis of PFS (time from randomization to progression or death from any cause) per INV was conducted. Results: After a median follow-up of 60.7 months (95% CI, 60.4-61.0), there was a 36% reduction in the risk of progression or death in AYAs receiving A+AVD vs ABVD (HR 0.64; 95% CI, 0.45-0.92; P = 0.013) with a 5-year PFS of 86.3% vs 79.4%, respectively, similar to the ITT population. The PFS benefit of A+AVD vs ABVD was independent of PET2 status; PET2 positivity (Deauville 4-5) was 6% and 8%, respectively. On the A+AVD arm, 81 AYAs (20%) had at least 1 subsequent anticancer therapy vs 96 AYAs (26%) on the ABVD arm; 26 AYAs (7%) received subsequent high dose chemotherapy and autologous stem cell transplant vs 32 AYAs (9%) on the A+AVD and ABVD arms, respectively. Resolution or improvement of peripheral neuropathy (PN) were similar in both arms; 224 AYAs (88%) on the A+AVD had resolution or improvement of PN vs 133 AYAs (89%) on the ABVD arm. Ongoing PN was predominantly Gr 1 (62%) and Gr 2 (26%), with 8 AYAs (13%) on the A+AVD arm and 1 AYA (5%) on the ABVD arm reporting ongoing Gr 3 PN. Finally, 7 AYAs (1.8%) and 5 AYAs (1.4%) on the A+AVD and ABVD arms, respectively, reported a secondary malignancy. Subsequent pregnancies were reported in female pts (44 A+AVD; 26 ABVD) and partners of male pts (31 A+AVD; 30 ABVD). No stillbirths were reported. All but 1 pt in each arm was < 40. Conclusions: Consistent with the ITT population, AYAs treated with A+AVD compared to ABVD had a durable PFS benefit at this significant 5-year milestone. No impact on the rate of secondary malignancies and a numerically greater number of pregnancies were observed, outcomes of interest to AYAs. Additionally, the majority of PN events improved or resolved over time. A+AVD should be considered a treatment option for AYAs with stage III/IV cHL. Clinical trial information: NCT01712490.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xfy完成签到,获得积分10
2秒前
阳炎完成签到,获得积分10
4秒前
行云流水完成签到,获得积分10
5秒前
6秒前
冷酷尔琴发布了新的文献求助10
10秒前
青水完成签到 ,获得积分10
14秒前
量子星尘发布了新的文献求助10
14秒前
14秒前
冷酷尔琴完成签到,获得积分10
14秒前
onevip完成签到,获得积分0
16秒前
小莫完成签到 ,获得积分10
18秒前
27秒前
theseus完成签到,获得积分10
28秒前
胡楠完成签到,获得积分10
30秒前
北国雪未消完成签到 ,获得积分10
31秒前
李振博完成签到 ,获得积分10
31秒前
41秒前
雪妮完成签到 ,获得积分10
44秒前
松松发布了新的文献求助20
47秒前
47秒前
iwsaml完成签到 ,获得积分10
47秒前
Caden完成签到 ,获得积分10
50秒前
xmhxpz完成签到,获得积分10
51秒前
was_3完成签到,获得积分10
51秒前
聪慧板凳完成签到,获得积分10
55秒前
1分钟前
buerzi完成签到,获得积分10
1分钟前
魁梧的盼望完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助30
1分钟前
1分钟前
wzk完成签到,获得积分10
1分钟前
称心翠容完成签到,获得积分10
1分钟前
LaixS完成签到,获得积分10
1分钟前
尊敬代亦发布了新的文献求助10
1分钟前
要笑cc完成签到,获得积分10
1分钟前
青珊发布了新的文献求助10
1分钟前
宣宣宣0733完成签到,获得积分10
1分钟前
俊逸吐司完成签到 ,获得积分10
1分钟前
ttxxcdx完成签到 ,获得积分10
1分钟前
胡质斌完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038029
求助须知:如何正确求助?哪些是违规求助? 3575740
关于积分的说明 11373751
捐赠科研通 3305559
什么是DOI,文献DOI怎么找? 1819224
邀请新用户注册赠送积分活动 892652
科研通“疑难数据库(出版商)”最低求助积分说明 815022